Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (241-250 of 368) with videos related to

Pageof 37
Sort By:
Hepatology (Baltimore, Md.)|August 31, 2010
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionJason Grebely, Kathy Petoumenos, Margaret Hellard, et al.
Antiviral Therapy|August 11, 2016
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studiesMarianne Martinello, Margaret Hellard, David Shaw, et al.
The Lancet. Global Health|October 28, 2017
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewLouisa Degenhardt, Amy Peacock, Samantha Colledge, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2020
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisJason Grebely, Lucy Tran, Louisa Degenhardt, et al.
Journal of Hepatology|September 10, 2014
Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatmentEsther J Aspinall, Sharon J Hutchinson, Naveed Z Janjua, et al.
Drug and Alcohol Review|October 7, 2024
Provider costs of treating opioid dependence with extended-release buprenorphine in AustraliaStella Settumba, Jeyran Shahbazi, Marianne Byrne, et al.
Journal of Viral Hepatitis|August 27, 2019
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort studyBeth Catlett, Francois M J Lamoury, Sahar Bajis, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trialsAshley Brown, Tania M Welzel, Brian Conway, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|April 29, 2015
A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission eventsAndrea D Olmstead, Jeffrey B Joy, Vincent Montoya, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Pageof 37

Showing results (241-250 of 368) with videos related to

Sort By:
Pageof 37
Hepatology (Baltimore, Md.)|August 31, 2010
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionJason Grebely, Kathy Petoumenos, Margaret Hellard, et al.
Antiviral Therapy|August 11, 2016
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studiesMarianne Martinello, Margaret Hellard, David Shaw, et al.
The Lancet. Global Health|October 28, 2017
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewLouisa Degenhardt, Amy Peacock, Samantha Colledge, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2020
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisJason Grebely, Lucy Tran, Louisa Degenhardt, et al.
Journal of Hepatology|September 10, 2014
Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatmentEsther J Aspinall, Sharon J Hutchinson, Naveed Z Janjua, et al.
Drug and Alcohol Review|October 7, 2024
Provider costs of treating opioid dependence with extended-release buprenorphine in AustraliaStella Settumba, Jeyran Shahbazi, Marianne Byrne, et al.
Journal of Viral Hepatitis|August 27, 2019
Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort studyBeth Catlett, Francois M J Lamoury, Sahar Bajis, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 1, 2019
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trialsAshley Brown, Tania M Welzel, Brian Conway, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|April 29, 2015
A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission eventsAndrea D Olmstead, Jeffrey B Joy, Vincent Montoya, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profilesLindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Pageof 37